Reducing Tobacco-Related Disability in Chronic Smokers

Area of Science:

• Public Health
• Cardiovascular Medicine
• Genetics

Background:

• Tobacco use is the leading preventable cause of global mortality.
• A significant number of smokers are unable or unwilling to quit, necessitating alternative risk reduction strategies.
• Individual risk in smokers is influenced by smoking intensity, duration, co-existing risk factors, environmental stressors, and genetic/epigenetic factors.

Purpose of the Study:

• To explore methods for identifying chronic smokers at higher risk for adverse events.
• To investigate potential interventions for reducing cardiovascular risk in high-risk smokers.
• To emphasize the need for identifying and treating smokers unwilling or unable to quit.

Main Methods:

• Review of recent data on inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP).
• Assessment of targeted imaging techniques for risk identification in smokers.
• Consideration of pharmacological interventions like aspirin and statins for cardiovascular risk reduction.

Main Results:

• High-sensitivity C-reactive protein (hs-CRP) and specific imaging modalities show promise in identifying some smokers with elevated risk.
• Smoking is associated with a prothrombotic state, suggesting potential benefits from aspirin and expanded statin use.
• Further research is required to validate these interventions for smokers not currently meeting criteria.

Conclusions:

• While smoking cessation remains paramount, strategies to identify and manage high-risk smokers are essential.
• Inflammatory markers and imaging can aid in identifying individuals who may benefit from targeted risk reduction therapies.
• Interventions such as aspirin and statins warrant further investigation for cardiovascular risk mitigation in this population.